JP2022543139A5 - - Google Patents

Info

Publication number
JP2022543139A5
JP2022543139A5 JP2022506965A JP2022506965A JP2022543139A5 JP 2022543139 A5 JP2022543139 A5 JP 2022543139A5 JP 2022506965 A JP2022506965 A JP 2022506965A JP 2022506965 A JP2022506965 A JP 2022506965A JP 2022543139 A5 JP2022543139 A5 JP 2022543139A5
Authority
JP
Japan
Prior art keywords
cells
population
gvhd
phenotype
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2020/050865 external-priority patent/WO2021024264A2/en
Publication of JP2022543139A publication Critical patent/JP2022543139A/ja
Publication of JP2022543139A5 publication Critical patent/JP2022543139A5/ja
Pending legal-status Critical Current

Links

JP2022506965A 2019-08-06 2020-08-06 ハプロタイプ一致幹細胞移植における抗ウイルスセントラルメモリーｃｄ８＋ベト細胞 Pending JP2022543139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962883164P 2019-08-06 2019-08-06
US62/883,164 2019-08-06
PCT/IL2020/050865 WO2021024264A2 (en) 2019-08-06 2020-08-06 Anti-viral central memory cd8+ veto cells in haploidentical stem cell transplantation

Publications (2)

Publication Number Publication Date
JP2022543139A JP2022543139A (ja) 2022-10-07
JP2022543139A5 true JP2022543139A5 (https=) 2023-08-15

Family

ID=74504020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506965A Pending JP2022543139A (ja) 2019-08-06 2020-08-06 ハプロタイプ一致幹細胞移植における抗ウイルスセントラルメモリーｃｄ８＋ベト細胞

Country Status (10)

Country Link
US (1) US20230398214A1 (https=)
EP (1) EP4009991A4 (https=)
JP (1) JP2022543139A (https=)
CN (1) CN114466925A (https=)
AU (1) AU2020326568A1 (https=)
BR (1) BR112022001988A2 (https=)
CA (1) CA3149379A1 (https=)
IL (1) IL290337A (https=)
MX (1) MX2022001578A (https=)
WO (1) WO2021024264A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500277A (ja) * 2019-11-05 2023-01-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Ｔ細胞媒介性自己免疫疾患の治療におけるベト細胞の使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008486A (es) * 2003-02-10 2005-11-17 Northwest Biotherapeutics Inc Celulas presentadoras de antigeno cd14+ cultivadas.
WO2007137300A2 (en) * 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US9738872B2 (en) * 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
WO2013035099A1 (en) * 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP6715482B2 (ja) * 2014-07-18 2020-07-01 国立大学法人京都大学 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
EP3322424B1 (en) * 2015-07-16 2023-10-11 Yeda Research and Development Co., Ltd. Use of anti third party central memory t cells
IL263924B2 (en) * 2016-06-27 2025-03-01 Yeda Res & Dev Voto cells produced from memory T cells

Similar Documents

Publication Publication Date Title
JP7244461B2 (ja) 養子細胞療法のための改良型細胞培養方法
US20230383250A1 (en) Methods of cell culture for adoptive cell therapy
Murphy et al. TNF‐α/IL‐1β—licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell‐mediated induction of Foxp3+ regulatory T cells in the lung
AU783429B2 (en) Veto cells effective in preventing graft rejection and devoid of graft versus host potential
EP3654994B1 (en) A modulatable switch for selection of donor modified cells
Sun et al. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a production assistant for cell therapy (PACT) translational application
JP2019520823A5 (https=)
WO2021034674A1 (en) Third party virus-specific t cell compositions, and methods of making and using the same in anti-viral prophylaxis
CA3249498A1 (en) ALLOGENIC T LYMPHOCYTES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
Bojanic et al. Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
JP2022543139A5 (https=)
CN117106061B (zh) 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用
JP2024538258A5 (https=)
RU2022105687A (ru) Противовирусные клетки вето центральной памяти cd8+ при гаплоидентичной трансплантации стволовых клеток
CN111548998B (zh) 一种分泌pd-1抗体的长寿浆细胞及其制备方法与应用
CN113832101A (zh) 自然杀伤细胞体外高效扩增的制备方法
US20250353892A1 (en) Virus-specific recombinant t cell receptors and t cells comprising them
Otsu et al. Stem Cell Gene Therapy for ADA-Deficiency without Myelopreparative Conditioning
Quinn Memory CD8+ T cells remain functional throughout an ongoing persistent infection: Implications for antigen-specific immune reconstitution and boosting
RU2019101826A (ru) Вето-клетки, полученные из т-клеток памяти
WO2021101466A1 (en) A method for producing multivirus specific t cells
Moss ES02. 03 Principles of immunotherapy.
Drawz et al. Adoptive immunotherapy
Querol et al. Immunobiology of Cord Blood Cells
CN101137292A (zh) 用于移植的神经干细胞的免疫保护的骨髓基质细胞